allergic rhinitis
Conditions
Interventions
Intervention group:high-frequency ultrasound-guided sphenopalatine ganglion acupuncture combined with heat-sensitive moxibustion
Control group:Budesonide Nasal Spray therapy
Sponsors
The Second Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Participants meeting the diagnostic criteria, mainly those with moderate-to-severe perennial allergic rhinitis (AR). The Total Nasal Symptom Score (TNSS) was used as the primary defining criterion. TNSS is the sum of scores for 4 nasal symptoms, nasal obstruction, rhinorrhea, sneezing, and nasal itch, with each symptom rated on a scale of 0 (no symptom) to 4 (severe symptom). The total TNSS ranges from 0 to 16. Specifically, a TNSS of > 0 and 4 indicates moderate-to-severe AR. 2. Heat-sensitive moxibustion sensations were detected at points 1 cun superior, inferior, left and right to Yintang (EX-HN3). 3. Aged 18 to 65 years, regardless of gender;Voluntarily participated in this clinical observation and signed the informed consent form. 4. Able to comply with the physician’s treatment arrangements and coordinate with the treatment and follow-up procedures. 5. With clear consciousness, capable of accurately describing moxibustion sensations and cooperating with clinical operations. 6. The patient had normal consciousness, was able to accurately describe moxibustion sensations, and cooperated well during the procedure. 7. Voluntarily participated in the trial and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Participants with severe concurrent diseases of the cardiovascular and cerebrovascular systems, liver, kidneys, hematopoietic system, or other major organs. 2. Participants with other nasal disorders, such as chronic rhinitis, sinusitis, or the like. 3. Participants with psychiatric disorders; pregnant or lactating women. 4. Participants with concurrent upper respiratory tract diseases, such as asthma, bronchitis, or others. 5. Participants with a history of needle syncope, moxibustion syncope, or rejection of acupuncture and moxibustion. 6. Participants intolerant to moxa smoke.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Nasal Symptom Score, TNSS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total Non-Nasal Symptom Score, TNNSS;Rhinoconjunctivitis Quality of Life Questionnaire, RQLQ; | — |
Countries
China
Contacts
Public ContactXiong Jun
The Second Affiliated Hospital of Nanchang University
Outcome results
None listed